Pharmaceutical logistics provider LogiCare3PL, a BioCare company, said on Monday that it is supporting the commercial launch of VYKAT XR, a newly FDA-approved therapy from US biopharmaceutical company Soleno Therapeutics Inc (NASDAQ:SLNO).

VYKAT XR is the first and only treatment indicated for hyperphagia in patients with Prader-Willi syndrome (PWS).

LogiCare3PL said that this milestone marks a significant advancement for the PWS community. For the first time, individuals with PWS, who live with chronic, insatiable hunger caused by hyperphagia, have access to a therapy designed to directly address this debilitating symptom.

"This is a breakthrough moment for families affected by Prader-Willi syndrome," said Kevin Kissling, LogiCare3PL vice president and general manager. "We're proud to partner with Soleno Therapeutics to help bring VYKAT XR to patients and support timely access to this long-awaited treatment."